Characterization of Potential Adverse Outcome Pathways Related to Metabolic Outcomes and Exposure to Per- and Polyfluoroalkyl Substances Using Artificial Intelligence

Overview

Journal Toxics

Date 2022 Aug 25

PMID 36006128

Authors

Andreas-Marius Kaiser

Maryam Zare Jeddi

Maria Uhl

Florence Jornod

Mariana F Fernandez

Karine Audouze

Affiliations

Soon will be listed here.

Abstract

Human exposure to per- and polyfluoroalkyl substances (PFAS) has been associated with numerous adverse health effects, depending on various factors such as the conditions of exposure (dose/concentration, duration, route of exposure, etc.) and characteristics associated with the exposed target (e.g., age, sex, ethnicity, health status, and genetic predisposition). The biological mechanisms by which PFAS might affect systems are largely unknown. To support the risk assessment process, AOP-helpFinder, a new artificial intelligence tool, was used to rapidly and systematically explore all available published information in the PubMed database. The aim was to identify existing associations between PFAS and metabolic health outcomes that may be relevant to support building adverse outcome pathways (AOPs). The collected information was manually organized to investigate linkages between PFAS exposures and metabolic health outcomes, including dyslipidemia, hypertension, insulin resistance, and obesity. Links between PFAS exposure and events from the existing metabolic-related AOPs were also retrieved. In conclusion, by analyzing dispersed information from the literature, we could identify some associations between PFAS exposure and components of existing AOPs. Additionally, we identified some linkages between PFAS exposure and metabolic outcomes for which only sparse information is available or which are not yet present in the AOP-wiki database that could be addressed in future research.

Citing Articles

Per- And Poly-Fluoroalkyl Substances (PFAS) Exposure and Risk of Breast, and Female Genital Cancers: A Systematic Review and Meta-Analysis.

Seyyedsalehi M, Maria Kappil E, Zhang S, Zheng T, Boffetta P Med Lav. 2024; 115(6):e2024043.

PMID: 39697081 PMC: 11734636. DOI: 10.23749/mdl.v115i6.16330.

Adverse outcome pathway for the neurotoxicity of Per- and polyfluoroalkyl substances: A systematic review.

Li S, Qin S, Zeng H, Chou W, Oudin A, Kanninen K Eco Environ Health. 2024; 3(4):476-493.

PMID: 39605965 PMC: 11599988. DOI: 10.1016/j.eehl.2024.08.002.

A novel method to derive a human safety limit for PFOA by gene expression profiling and modelling.

Silva A, Loizou G, McNally K, Osborne O, Potter C, Gott D Front Toxicol. 2024; 6:1368320.

PMID: 38577564 PMC: 10991825. DOI: 10.3389/ftox.2024.1368320.

Effect of Per and Poly-Fluoroalkyl Substances on Pregnancy and Child Development.

Kilari T, S A, Suresh A, Begum R, Begum R, Singh A Curr Pediatr Rev. 2024; 21(2):142-153.

PMID: 38213179 DOI: 10.2174/0115733963267526231120110100.

Reduced Birth Weight and Exposure to Per- and Polyfluoroalkyl Substances: A Review of Possible Underlying Mechanisms Using the AOP-HelpFinder.

Gundacker C, Audouze K, Widhalm R, Granitzer S, Forsthuber M, Jornod F Toxics. 2022; 10(11).

PMID: 36422892 PMC: 9699222. DOI: 10.3390/toxics10110684.

References

Saklayen M . The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018; 20(2):12. PMC: 5866840. DOI: 10.1007/s11906-018-0812-z. View

Jain R, Ducatman A . Roles of gender and obesity in defining correlations between perfluoroalkyl substances and lipid/lipoproteins. Sci Total Environ. 2018; 653:74-81. DOI: 10.1016/j.scitotenv.2018.10.362. View

Buhrke T, Kruger E, Pevny S, Rossler M, Bitter K, Lampen A . Perfluorooctanoic acid (PFOA) affects distinct molecular signalling pathways in human primary hepatocytes. Toxicology. 2015; 333:53-62. DOI: 10.1016/j.tox.2015.04.004. View

Huang M, Jiao J, Zhuang P, Chen X, Wang J, Zhang Y . Serum polyfluoroalkyl chemicals are associated with risk of cardiovascular diseases in national US population. Environ Int. 2018; 119:37-46. DOI: 10.1016/j.envint.2018.05.051. View

Huang P . A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009; 2(5-6):231-7. PMC: 2675814. DOI: 10.1242/dmm.001180. View

Carvaillo J, Barouki R, Coumoul X, Audouze K . Linking Bisphenol S to Adverse Outcome Pathways Using a Combined Text Mining and Systems Biology Approach. Environ Health Perspect. 2019; 127(4):47005. PMC: 6785233. DOI: 10.1289/EHP4200. View

Kataria A, Trachtman H, Malaga-Dieguez L, Trasande L . Association between perfluoroalkyl acids and kidney function in a cross-sectional study of adolescents. Environ Health. 2015; 14:89. PMC: 4654837. DOI: 10.1186/s12940-015-0077-9. View

Behr A, Plinsch C, Braeuning A, Buhrke T . Activation of human nuclear receptors by perfluoroalkylated substances (PFAS). Toxicol In Vitro. 2019; 62:104700. DOI: 10.1016/j.tiv.2019.104700. View

Zare Jeddi M, Soltanmohammadi R, Barbieri G, Fabricio A, Pitter G, Dalla Zuanna T . To which extent are per-and poly-fluorinated substances associated to metabolic syndrome?. Rev Environ Health. 2021; 37(2):211-228. DOI: 10.1515/reveh-2020-0144. View

10.

Mancini F, Rajaobelina K, Praud D, Dow C, Antignac J, Kvaskoff M . Nonlinear associations between dietary exposures to perfluorooctanoic acid (PFOA) or perfluorooctane sulfonate (PFOS) and type 2 diabetes risk in women: Findings from the E3N cohort study. Int J Hyg Environ Health. 2018; 221(7):1054-1060. DOI: 10.1016/j.ijheh.2018.07.007. View

11.

Schrenk D, Bignami M, Bodin L, Chipman J, Del Mazo J, Grasl-Kraupp B . Risk to human health related to the presence of perfluoroalkyl substances in food. EFSA J. 2020; 18(9):e06223. PMC: 7507523. DOI: 10.2903/j.efsa.2020.6223. View

12.

Koshy T, Attina T, Ghassabian A, Gilbert J, Burdine L, Marmor M . Serum perfluoroalkyl substances and cardiometabolic consequences in adolescents exposed to the World Trade Center disaster and a matched comparison group. Environ Int. 2017; 109:128-135. PMC: 5660646. DOI: 10.1016/j.envint.2017.08.003. View

13.

Rugard M, Coumoul X, Carvaillo J, Barouki R, Audouze K . Deciphering Adverse Outcome Pathway Network Linked to Bisphenol F Using Text Mining and Systems Toxicology Approaches. Toxicol Sci. 2019; 173(1):32-40. PMC: 6944215. DOI: 10.1093/toxsci/kfz214. View

14.

Xu J, Shimpi P, Armstrong L, Salter D, Slitt A . PFOS induces adipogenesis and glucose uptake in association with activation of Nrf2 signaling pathway. Toxicol Appl Pharmacol. 2015; 290:21-30. PMC: 4742372. DOI: 10.1016/j.taap.2015.11.002. View

15.

Jain R . Concentration of selected liver enzymes across the stages of glomerular function: the associations with PFOA and PFOS. Heliyon. 2019; 5(7):e02168. PMC: 6667701. DOI: 10.1016/j.heliyon.2019.e02168. View

16.

Yang Q, Guo X, Sun P, Chen Y, Zhang W, Gao A . Association of serum levels of perfluoroalkyl substances (PFASs) with the metabolic syndrome (MetS) in Chinese male adults: A cross-sectional study. Sci Total Environ. 2017; 621:1542-1549. DOI: 10.1016/j.scitotenv.2017.10.074. View

17.

Kishi R, Nakajima T, Goudarzi H, Kobayashi S, Sasaki S, Okada E . The Association of Prenatal Exposure to Perfluorinated Chemicals with Maternal Essential and Long-Chain Polyunsaturated Fatty Acids during Pregnancy and the Birth Weight of Their Offspring: The Hokkaido Study. Environ Health Perspect. 2015; 123(10):1038-45. PMC: 4590753. DOI: 10.1289/ehp.1408834. View

18.

Li N, Liu Y, Papandonatos G, Calafat A, Eaton C, Kelsey K . Gestational and childhood exposure to per- and polyfluoroalkyl substances and cardiometabolic risk at age 12 years. Environ Int. 2021; 147:106344. PMC: 7856172. DOI: 10.1016/j.envint.2020.106344. View

19.

Shankar A, Xiao J, Ducatman A . Perfluoroalkyl chemicals and elevated serum uric acid in US adults. Clin Epidemiol. 2011; 3:251-8. PMC: 3191115. DOI: 10.2147/CLEP.S21677. View

20.

Zhao W, Cui R, Wang J, Dai J . Inhibition effects of perfluoroalkyl acids on progesterone production in mLTC-1. J Environ Sci (China). 2017; 56:272-280. DOI: 10.1016/j.jes.2016.08.026. View